Skip to Main Content
U.S. Department of Health & Human Services » National Institutes of Health
National Heart, Lung, and Blood Institute
Login | Register

Biologic Specimen and Data Repository Information Coordinating Center

  • Home (current)
  • Biospecimen and Data Resources
    • Overview
    • Studies
    • Teaching Datasets - Public Use Datasets
    • Renew Existing Data Use Agreement
    • Publications
    • Funding Opportunities
    • Non-BioLINCC Resources
  • Procedures and Forms
    • BioLINCC Handbook
    • Forms
    • Agreement Templates
  • Build/Submit New Collection
    • NHLBI Biorepository Guide
    • Submit Datasets
    • Submit Biospecimens and Datasets
  • Contact Us
Home > Studies > Acute Respiratory Distress Network (ARDSNet) Studies 10 and 12 Statins for Acutely Injured Lungs from Sepsis (SAILS)

Acute Respiratory Distress Network (ARDSNet) Studies 10 and 12 Statins for Acutely Injured Lungs from Sepsis (SAILS)

Accession Number
HLB01201414a

Study Type
Clinical Trial

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
2010 - 2013

NHLBI Division
DLD

Date Prepared
December 5, 2014

Last Updated
N/A

Clinical Trial URLs
https://clinicaltrials.gov/ct2/s...

Primary Publication URLs
http://www.ncbi.nlm.nih.gov/pubm...

Study Website
http://www.ardsnet.org/

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No

Commercial Use Specimen Restrictions Yes

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes, For Some Specimens

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Non-genetic use of biospecimens is restricted to research involving lung injury, other lung disease or critical care diseases. Use of biospecimens in genetic research is tiered to (1) research in acute respiratory distress syndrome (ARDS), or (2) research in other medical conditions. Biospecimens cannot be used directly to produce commercial products.

Objectives

The SAILS trial was intended to assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI) and test the hypothesis that rosuvastatin therapy would improve the clinical outcomes of critically ill patients with sepsis-associated acute respiratory distress syndrome (ARDS).

Background

In ARDS, inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis.

Subjects

Patients were eligible for enrollment if they were receiving positive-pressure mechanical ventilation through an endotracheal tube, had a ratio of the partial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of 300 or less, and had bilateral infiltrates on chest radiography that were consistent with pulmonary edema, without evidence of left atrial hypertension. Additionally, the subjects needed to meet at least one criterion for a systemic inflammatory response: a white blood cell count greater than 12,000 or less than 4,000 or at least 10% band forms, or a core body temperature of more than 38°C or less than 36°C.

Design

Patients were randomly assigned in permuted blocks to receive either enteral rosuvastatin or placebo. A 40 mg loading dose of the study drug was administered within four hours after randomization. Subsequently, maintenance doses of 20 mg were administered daily until the third day after discharge from the intensive care unit, study day 28, hospital discharge, or death, whichever came first. The primary outcome measure was mortality before hospital discharge home or until study day 60 if the patient was still in a health care facility. Secondary outcome measures included the number of ventilator-free days to day 28, organ-failure-free days to day 14, and ICU-free days to day 28.

Conclusions

The study was stopped because of futility after 745 of an estimated 1000 patients had been enrolled. There was no significant difference between study groups in 60 day in-hospital mortality or in mean ventilator-free days. The rosuvastatin group had fewer days free of hepatic or renal failure. Thus, rosuvastatin therapy did not improve clinical outcomes in patients with sepsis-associated ARDS and may have contributed to hepatic and renal organ dysfunction.

Additional Details

Study Population

Subjects:

rosuvastatin: 379

placebo: 366

 

Age:
 

SAILS placebo

SAILS rosuvastatin

All

N

%

N

%

N

%

17-20

7

1.91

7

1.85

14

1.88

21-25

8

2.19

11

2.90

19

2.55

26-30

19

5.19

20

5.28

39

5.23

31-35

13

3.55

24

6.33

37

4.97

36-40

27

7.38

30

7.92

57

7.65

41-45

32

8.74

27

7.12

59

7.92

46-50

26

7.10

39

10.29

65

8.72

51-55

51

13.93

37

9.76

88

11.81

56-60

59

16.12

46

12.14

105

14.09

61-65

40

10.93

35

9.23

75

10.07

65-70

32

8.74

35

9.23

67

8.99

71-75

21

5.74

23

6.07

44

5.91

76-80

14

3.83

23

6.07

37

4.97

81-85

14

3.83

13

3.43

27

3.62

86-89

3

0.82

9

2.37

12

1.61

 
Sex:

 

SAILS placebo

SAILS rosuvastatin

All

N

%

N

%

N

%

Female

185

50.55

195

51.45

380

51.01

Male

181

49.45

184

48.55

365

48.99

 
Race:

 

SAILS placebo

SAILS rosuvastatin

All

N

%

N

%

N

%

Not reported

10

2.73

14

3.69

24

3.22

White

289

78.96

301

79.42

590

79.19

African American

53

14.48

52

13.72

105

14.09

Other

14

3.83

12

3.17

26

3.49

 

 

SAILS placebo

SAILS rosuvastatin

All

N

%

N

%

N

%

Hispanic or Latino

40

10.93

46

12.14

86

11.54

Not Hispanic or Latino

326

89.07

333

87.86

659

88.46

 

Available Biospecimens

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):

12/06/2018

  Plasma Urine Total
Day 0 3,447 2,663 6,110
Day 3 3,385 2,321 5,706
Day 6 2,521 1,661 4,182
Day 12 98 0 98
Unknown 6 8 14

 
Visits (Subjects):

12/06/2018

  Plasma
Total number of subjects Average volume (ml) per subject
Day 0 725 3.67
Day 3 649 3.41
Day 6 507 4.65
Day 12 25 6.23
Unknown 1 12.00
 
  Urine
Total number of subjects Average volume (ml) per subject
Day 0 691 5.95
Day 3 606 5.92
Day 6 429 6.03
Unknown 1 16.00

 

Requests for Open BioLINCC Studies are submitted through this website. Click the Request button to begin.

Resources Available

Specimens and Study Datasets

Study Catalog

Study Publications (2)

Materials Available

  • Plasma
  • Urine
  • More Details

Study Documents

  • PDF Data Dictionary (PDF - 7.2 MB)
  • PDF Forms (PDF - 849.3 KB)
  • PDF Protocol (PDF - 1.5 MB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

  • About Us
  • Glossary
  • Contact
  • Privacy Policy
  • Accessibility
  • FOIA

  • U.S. Department of Health & Human Services
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • USA.gov
NIH… Turning Discovery Into Health®